Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.

Abstract : PURPOSE: The aim of this prospective study was to evaluate whether [¹⁸F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in patients with inoperable (stage IIIA to IV) non-small cell lung cancer patients. PATIENTS AND METHODS: Three [¹⁸F]FDG-PET/CT scans were acquired in 12 patients before (5±4 days) and after 9±3 days (early PET) and 60±6 days (late PET) of erlotinib therapy. Conventional evaluation, including at least chest CT (baseline versus after 8 weeks of treatment), was performed according to RECIST 1.1 criteria. Change in [¹⁸F]FDG uptake was compared with conventional response, progression-free survival (PFS), and overall survival (OS). RESULTS: By using ROC analysis, the Area Under the Curve for prediction of metabolic non-progressive disease (mNP) by early PET was 0.86 (95% CI, 0.62 to 1.1; P = 0.04) at a cut-off of 21.6% reduction in maximum Standardized Uptake Value (SUVmax). This correctly classified 11/12 patients (7 with true progressive disease; 4 with true non-progressive disease; 1 with false progressive disease). Non-progressive disease after 8 weeks of treatment according to RECIST 1.1 criteria was significantly more frequent in patients classified mNP (P = 0.01, Fisher's exact test). mNP patients showed prolonged PFS (HR = 0.27; 95% CI, 0.04 to 0.59; P<0.01) and OS (HR = 0.34; 95% CI, 0.06 to 0.84; P = 0.03). Late PET analysis provided concordant results. CONCLUSION: Morphologic response, PFS and OS survival in non-small cell lung cancer patients can be predicted by [¹⁸F]FDG-PET/CT scan within 2 weeks after starting erlotinib therapy.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.univ-angers.fr/hal-03179505
Contributeur : Okina Université d'Angers <>
Soumis le : mercredi 24 mars 2021 - 12:22:56
Dernière modification le : jeudi 25 mars 2021 - 15:28:07

Fichier

journal.pone_.0087629.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Mammar Hachemi, Olivier-François Couturier, Laurent Vervueren, Pacôme Fosse, Franck Lacœuille, et al.. [¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.. PLoS ONE, Public Library of Science, 2014, 9, pp.e87629. ⟨10.1371/journal.pone.0087629⟩. ⟨hal-03179505⟩

Partager

Métriques

Consultations de la notice

19

Téléchargements de fichiers

21